子宫肌瘤组织中miR-590、miR-16表达的临床意义

Abstract
Figure/Table
References (25)
Related Citation (14)

Download: PDF (507 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore clinical significance of the expression of microribonucleic acid-590 (miR-590) and miR-16 in hysteromyoma tissue. Methods One hundred and eighty-six patients with hysteromyoma treated in Suzhou Hospital of Integrated Traditional Chinese and Western Medicine, Jiangsu Province from October 2018 to August 2020 were selected as study group, a total of 120 patients with uterine prolapse were selected as the control group. The expression levels of miR-590 and miR-16 in hysteromyoma tissue and normal uterine tissues were detected by real-time quantitative PCR. The influencing factors of hysteromyoma was explored by using multivariate logistic regression analysis. Pearson correlation was used to analyze the relationship between the expression levels of miR-590, miR-16 and the size, number of hysteromyoma. Results The expression level of miR-590 in study group was higher than that in control group, and the expression level of miR-16 was lower than that in control group (P < 0.05). The proportion of diabetes mellitus, menstrual disorders, and reproductive tract inflammation in study group were higher than those in control group, the number of miscarriages in study group was more than that in control group (P < 0.05). Logistic regression analysis showed that menstrual disorder, genital tract inflammation, and the expression levels of miR-590 and miR-16 in uterine tissue were the influencing factors of hysteromyoma (OR = 2.818, 2.751, 3.888, 3.476, P ＜ 0.05). The expression level of miR-590 was positively correlated with the size and number of hysteromyomas (r = 0.767, 0.795, P < 0.05). The expression level of miR-16 was negatively correlated with the size and number of hysteromyomas (r = -0.743, -0.792, P < 0.05). Conclusion MiR-590 is highly expressed in hysteromyoma tissue while miR-16 is low. The expression levels of miR-590 and miR-16 are related to the occurrence of hysteromyoma.

Key words： miR-590 miR-16 Hysteromyoma Myoma diameter Myoma number

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HUANG Yan1 ZHOU Yuzhen1 PAN Xiaohong2 ZHU Qianmeng1 ZHANG Yuying1▲

Cite this article:

HUANG Yan1 ZHOU Yuzhen1 PAN Xiaohong2 ZHU Qianmeng1 ZHANG Yuying1▲. Clinical significance of the expression of miR-590 and miR-16 in hysteromyoma tissue[J]. 中国医药导报, 2022, 19(20): 83-86.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2022/V19/I20/83

[1] Giuliani E，As-Sanie S，Marsh EE. Epidemiology and management of uterine fibroids [J]. Int J Gynaecol Obstet，2020，149（1）：3-9.
[2] Manyonda I，Belli AM，Lumsden MA，et al. Uterine-artery embolization or myomectomy for uterine fibroids [J]. N Engl J Med，2020，383（5）：440-451.
[3] Ciebiera M，W?覥odarczyk M，Zgliczyński S，et al. The role of miRNA and related pathways in pathophysiology of uterine fibroids-from bench to bedside [J]. Int J Mol Sci，2020，21（8）：3016.
[4] Ali M，Esfandyari S，Al-Hendy A. Evolving role of microRNAs in uterine fibroid pathogenesis：filling the gap [J]. Fertil Steril，2020，113（6）：1167-1168.
[5] Salem M，O’Brien JA，Bernaudo S，et al. MiR-590-3p promotes ovarian cancer growth and metastasis via a novel foxa2-versican pathway [J]. Cancer Res，2018，78（15）：4175-4190.
[6] Pekarsky Y，Balatti V，Croce CM. BCL2 and miR-15/16：from gene discovery to treatment [J]. Cell Death Differ，2018，25（1）：21-26.
[7] 子宫肌瘤的诊治中国专家共识专家组.子宫肌瘤的诊治中国专家共识[J].中华妇产科杂志，2017，52（12）：793-800.
[8] Donnez J，Arriagada P，Donnez O，et al. Emerging treatment options for uterine fibroids [J]. Expert Opin Emerg Drugs，2018，23（1）：17-23.
[9] Ulin M，Ali M，Chaudhry ZT，et al. Uterine fibroids in menopause and perimenopause [J]. Menopause，2020，27（2）：238-242.
[10] 韩旭东，杜丽芳，平春枝，等.加速康复外科模式下不同镇痛方法对开腹子宫肌瘤剔除术患者术后康复的影响[J].中国医药导报，2020，17（10）：109-112.
[11] Kim YJ，Kim YY，Shin JH，et al. Variation in microrna expression profile of uterine leiomyoma with endometrial cavity distortion and endometrial cavity non-distortion [J]. Int J Mol Sci，2018，19（9）：252-258.
[12] 马陈美，郎妙双，邵卓.米非司酮治疗子宫肌瘤的疗效及对患者外周血microRNA-18a和microRNA-200a水平的影响[J].中国妇幼保健，2020，35（9）：1733-1735.
[13] 丁亚，庞旭姣，邢景娜，等.子宫内膜癌组织中miRNA-302c的表达变化及其意义[J].现代消化及介入诊疗，2019， 8（1）：30-31.
[14] Yang L，Gao C. MiR-590 inhibits endothelial cell apoptosis by inactivating the TLR4/NF-κB pathway in athero-sclerosis [J]. Yonsei Med J，2019，60（3）：298-307.
[15] 卜德永，贾红燕.miRNA-16抑制乳腺癌细胞增殖和迁移的体外研究[J].肿瘤研究与临床，2017，29（6）：366-369.
[16] 王文尖，罗琼，覃世运，等.三种microRNA在胃癌患者中的表达及临床意义[J].中国免疫学杂志，2019，35（11）：1363-1367，1372.
[17] 王光宇，胡明华.miR-16-5p在肝癌组织中的表达及其对细胞增殖、侵袭及迁移的影响[J].安徽医药，2020，8（5）：21-26.
[18] Gagnon JD，Kageyama R，Shehata HM，et al. MiR-15/16 restrain memory T cell differentiation，cell cycle，and survival [J]. Cell Rep，2019，28（8）：2169-2181.
[19] 薛宏.子宫肌瘤发病相关因素分析及对Ki-67，P16和P53表达研究[J].中国妇幼保健，2018，33（17）：33-35.
[20] Duc NM，Keserci B. Review of influential clinical factors in reducing the risk of unsuccessful MRI-guided HIFU treatment outcome of uterine fibroids [J]. Diagn Interv Radiol，2018，24（5）：283-291.
[21] 徐纳佳，涂权梅，朱雪琼.子宫肌瘤和代谢综合征的相关性研究[J].浙江医学，2020，42（2）：33-36.
[22] Ma Z，Wang Y，He B，et al. Expression of miR-590 in lung cancer and its correlation with prognosis [J]. Oncol Lett，2018，15（2）：1753-1757.
[23] 陈晓杰，刘平.子宫颈鳞状细胞癌组织中LncRNA HCG11和miR-590-3p的表达及其与预后的关系[J].肿瘤防治研究，2018，45（3）：148-153.
[24] Kim KM，Han CY，Kim JY，et al. Gα12 overexpression induced by miR-16 dysregulation contributes to liver fibrosis by promoting autophagy in hepatic stellate cells [J]. J Hepatol，2018，68（3）：493-504.
[25] 杨登科，钱海宁，方震.miR-15a与miR-16-1在前列腺癌患者血清中的表达及意义[J].检验医学与临床，2020， 17（5）：691-693.